{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-095676","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.263673+00:00","generated_at":"2026-05-17T05:03:35.467240+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NanoViricides extends CEO/CFO contracts; raises CEO line of credit to $3M through 2027","bullets":["President/CEO Diwan term extended to June 30, 2026; base salary $400,000/yr; granted 10,204 Series A preferred shares vesting quarterly.","CFO Vyas term extended to June 30, 2026; compensation $10,800/month; health insurance reimbursement up to $2,500/month.","CEO Diwan's line of credit increased from $2M to $3M; maturity extended to March 31, 2027; 12% interest; secured by company property."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-095676","json":"https://secwatch.observer/filing/0001104659-25-095676.json","markdown":"https://secwatch.observer/filing/0001104659-25-095676.md","text":"https://secwatch.observer/filing/0001104659-25-095676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465925095676/0001104659-25-095676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465925095676/tm2527703d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:03:35.467240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}